Who are ingenol mebutate 0.05% gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inggenol Mebutate 0.015%, Ingenol mebutate gel 0.05 %, Generic Ingenol Mebutate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ingenol-mebutate-0-05-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ingenol mebutate 0.05% gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ingenol mebutate 0.05% gel (ingenol mebutate 0.05% gel) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protein kinase C activator. Area: Dermatology/Oncology.

marketed Protein kinase C activator Protein kinase C (PKC) Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ingenol mebutate 0.05% gel (ingenol mebutate 0.05% gel) — Neal D. Bhatia, MD. Ingenol mebutate activates protein kinase C (PKC) to induce rapid necrosis of actinic keratosis cells and promote immune-mediated clearance of damaged skin.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ingenol mebutate 0.05% gel TARGET	ingenol mebutate 0.05% gel	Neal D. Bhatia, MD	marketed	Protein kinase C activator	Protein kinase C (PKC)
Inggenol Mebutate 0.015%	Inggenol Mebutate 0.015%	Goldman, Butterwick, Fitzpatrick and Groff	marketed	Protein kinase C activator	Protein kinase C (PKC)
Ingenol mebutate gel 0.05 %	Ingenol mebutate gel 0.05 %	LEO Pharma	phase 3	Protein kinase C activator	Protein kinase C (PKC)
Generic Ingenol Mebutate	Generic Ingenol Mebutate	Actavis Inc.	phase 3	Protein kinase C activator	Protein kinase C (PKC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protein kinase C activator class)

Actavis Inc. · 1 drug in this class
Goldman, Butterwick, Fitzpatrick and Groff · 1 drug in this class
LEO Pharma · 1 drug in this class
Neal D. Bhatia, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ingenol mebutate 0.05% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/ingenol-mebutate-0-05-gel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab